Patents Assigned to Life Sciences Research Partners vzw.
  • Patent number: 10982196
    Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from an intracellular pathogen-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or treatment of infection with an intracellular pathogen and in the manufacture of medicaments therefore.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: April 20, 2021
    Assignees: Life Sciences Research Partners VZW, Katholieke Universiteit Leuven
    Inventor: Jean-Marie Saint-Remy
  • Patent number: 10899795
    Abstract: The present invention relates to immunogenic peptides comprising a T-cell epitope. Said peptides are modified such that CD4+ T-cell responses are obtainable that are much stronger than the CD4+ T-cell responses obtained with the same peptides not comprising said modification. In particular, the modification is the addition of a cysteine, insertion of a cysteine or mutation into a cysteine of a residue at a position adjacent to but outside the MHC-binding site of the peptide. Further disclosed are the use of such modified peptides in treating, suppressing or preventing diseases such as infectious or allergic diseases and autoimmune diseases, in preventing or suppressing graft rejection, or in the eradication of tumor cells.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: January 26, 2021
    Assignees: LIFE SCIENCES RESEARCH PARTNERS VZW, KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventor: Jean-Marie Saint-Remy
  • Patent number: 10662232
    Abstract: The present invention provides novel peptides and homologues thereof. The peptides of the invention comprise (i) a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class II major histocompatibility complex (MHC) determinant and recognised by CD4+ T cell more specifically of an allergen or auto-antigen, coupled, optionally through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence. The peptides of the invention have been shown to be useful a medicine, more in particular for the prevention or treatment of immune disorders, more specifically of allergic disorders or autoimmune diseases. The present invention thus provides for the use of said peptides for the manufacture of a medicament for the prevention or treatment of an immune disorder and further provides for methods of treatment or preventing immune disorders by using said peptides.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: May 26, 2020
    Assignee: LIFE SCIENCES RESEARCH PARTNERS VZW
    Inventor: Jean-Marie Saint-Remy
  • Patent number: 10633707
    Abstract: Described are mismatch repair (MMR-)deficient tumors. Markers are presented herein having a high sensitivity to detect whether a tumor is mismatch repair deficient or not. The markers are particularly mutations in microsatellite regions. Accordingly, methods and materials are provided for diagnosing microsatellite instability of a tumor. Such a method comprises determining the presence of these markers. Further, kits are provided to detect the presence of these markers (or subsets thereof) in a sample.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: April 28, 2020
    Assignees: VIB VZW, Life Sciences Research Partners VZW
    Inventor: Diether Lambrechts
  • Patent number: 10617748
    Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a tumor-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the treatment of a tumor or in the treatment or prevention of a tumor relapse, and in the manufacture of medicaments therefore.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: April 14, 2020
    Assignees: LIFE SCIENCES RESEARCH PARTNERS VZW, KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventor: Jean-Marie Saint-Remy
  • Patent number: 10294529
    Abstract: The present application relates to the field of cancer, particularly to mismatch repair (MMR?) deficient tumors. New markers are presented herein that have a high sensitivity to detect whether a tumor is mismatch repair deficient or not. The markers are particularly mutations in microsatellite regions. Accordingly, methods are provided for diagnosing microsatellite instability of a tumor, comprising determining the presence of these markers. Further, kits are provided to detect the presence of these markers (or subsets thereof) in a sample.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: May 21, 2019
    Assignees: Life Sciences Research Partners VZW, VIB VZW
    Inventor: Diether Lambrechts
  • Patent number: 10149914
    Abstract: Described are nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. These are particularly useful for applications using gene therapy.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: December 11, 2018
    Assignees: VIB VZW, Life Sciences Research Partners VZW, Universiteit Gent
    Inventors: Marinee Chuah, Thierry Vandendriessche, Pieter De Bleser
  • Patent number: 10106601
    Abstract: The present application relates to the field of leukemias, and more in particular to how P1 GF inhibition can help to treat Philadelphia chromosome positive (Ph+) leukemias. Methods are provided for treating Ph+ leukemias by administering P1 GF inhibitors. Also disclosed are uses of P1 GF inhibitors in the treatment of Ph+ leukemias, or for the preparation of a medicament against Ph+ leukemias.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: October 23, 2018
    Assignees: VIB VZW, Life Sciences Research Partners VZW
    Inventors: Peter Carmeliet, Sonja Loges
  • Patent number: 10076576
    Abstract: The present invention relates to the field of oligopeptide prodrugs that are intended for the treatment of cancer. The selectivity of these prodrugs requires the presence of an (oligo)peptidic moiety and/or a protective capping group to ensure the prodrug stability in blood. It further in particular relates to the exemplary oligopeptidic moiety ALGP and to prodrugs comprising it. In particular it also relates to the capping group phosphonoacetyl and to prodrugs comprising this capping group.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: September 18, 2018
    Assignee: LIFE SCIENCES RESEARCH PARTNERS VZW
    Inventor: André Trouet
  • Patent number: 10041126
    Abstract: The disclosure relates to the field of biomarkers to diagnose a disease, more particularly to the field of biomarkers to diagnose cancer, and most particularly to colorectal cancer. Specifically, these biomarkers are expressed in monocytes of a subject, particularly circulating monocytes, as can be isolated from peripheral blood. The markers are particularly useful for early detection of cancer.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: August 7, 2018
    Assignees: VIB VZW, Life Sciences Research Partners VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventor: Massimiliano Mazzone
  • Publication number: 20180051345
    Abstract: The present application relates to the field of cancer, particular to hypoxic tumors. It was found that hypoxia is an important driver for hypermethylation of (promoters of) tumor suppressor genes. As this hypermethylation is a stable signature that is also present in circulating tumor DNA in peripheral blood, detecting this methylation pattern is a surrogate marker for tumor hypoxia. This can be used to adapt therapy as well.
    Type: Application
    Filed: March 4, 2016
    Publication date: February 22, 2018
    Applicants: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D, LIFE SCIENCES RESEARCH PARTNERS VZW
    Inventors: Diether LAMBRECHTS, Bernard THIENPONT
  • Patent number: 9862777
    Abstract: The present application relates to the field of single-domain antibodies (also called nanobodies), more particularly single-domain antibodies against SOD1 protein isoforms. It also relates to the use of these nanobodies in medicine. Accordingly, methods to treat a disease using these nanobodies are provided herein. The single-domain antibodies are particularly envisaged for treatment of ALS.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: January 9, 2018
    Assignees: VIB VZW, LIFE SCIENCES RESEARCH PARTNERS VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Wim Robberecht, Frederic Rousseau, Joost Schymkowitz
  • Patent number: 9861661
    Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a viral vector antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or suppression of immune responses to viral vectors and in the manufacture of medicaments therefore.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: January 9, 2018
    Assignees: LIFE SCIENCES RESEARCH PARTNERS VZW, KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventor: Jean-Marie Saint-Remy
  • Publication number: 20170209600
    Abstract: Described are nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. These are particularly useful for applications using gene therapy.
    Type: Application
    Filed: April 10, 2017
    Publication date: July 27, 2017
    Applicants: VIB VZW, Life Sciences Research Partners VZW, Universiteit Gent
    Inventors: Marinee Chuah, Thierry Vandendriessche, Pieter De Bleser
  • Patent number: 9617548
    Abstract: The present invention relates to nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: April 11, 2017
    Assignees: VIB VZW, Life Sciences Research Partners VZW, Universiteit Gent
    Inventors: Marinee Chuah, Thierry Vandendriessche, Pieter De Bleser
  • Publication number: 20160166532
    Abstract: This disclosure relates to the field of angiogenesis, more particularly to the field of pathological angiogenesis. In particular, the disclosure has found that inhibitors reducing the activity of the enzyme carnitine palmitoyltransferase 1A can be used for treatment of diseases in which pathological angiogenesis is involved. In particular, the disclosure provides siRNAs directed against carnitine palmitoyltransferase 1A for the treatment of pathological angiogenesis. The disclosure also provides the use of a therapeutically effective amount of inhibitors of carnitine palmitoyltransferase 1A, or a pharmaceutically acceptable salt thereof, for the treatment of pathological angiogenesis.
    Type: Application
    Filed: July 25, 2014
    Publication date: June 16, 2016
    Applicant: Life Sciences Research Partners VZW
    Inventors: Peter Carmeliet, Sandra Schoors
  • Patent number: 9353164
    Abstract: The present invention relates to nucleic acid regulatory elements that are able to enhance cardiac-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: May 31, 2016
    Assignees: VIB VZW, Life Sciences Research Partners VZW, Universiteit Gent
    Inventors: Lay Khim Chuah, Thierry Vandendriessche, Pieter De Bleser
  • Patent number: 9249202
    Abstract: The peptides of the invention comprise (i) a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class II major histocompatibility complex (MHC) determinant and recognized by a CD4+ T cell, more specifically, of an allergen or autoantigen, coupled, optionally, through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence. The peptides may be used for the prevention or treatment of immune disorders, more specifically, of allergic disorders or autoimmune diseases. The present invention thus provides methods of treatment or preventing immune disorders by using such peptides.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: February 2, 2016
    Assignees: Life Sciences Research Partners VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventor: Jean-Marie Saint-Remy
  • Patent number: 9238028
    Abstract: The disclosure relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, such as Charcot-Marie-Tooth (CMT) disease. It is shown that this disease is associated with decreased acetylated tubulin levels, which can be overcome by inhibition of histone deacetylases (HDACs). Using HDAC inhibitors, it is shown herein that the symptoms of the CMT phenotype can be overcome both in vitro and in vivo. Also provided herein are two different mouse models of CMT disease.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: January 19, 2016
    Assignees: VIB VZW, Life Sciences Research Partners VZW
    Inventors: Ludo Van Den Bosch, Constantin Van Outryve d'Ydewalle, Wim Robberecht
  • Patent number: 9234025
    Abstract: The present invention relates to an extracellular binding domain for an allosteric inhibitor, whereby said binding domain is derived from a single membrane span tyrosine kinase receptor. More specifically, the invention relates to an extracellular domain derived from a Fibroblast Growth Factor Receptor (FGFR). It further relates to the use of this domain for the identification of similar domains in the extracellular part of other tyrosine kinase receptors, and to a screening method for identification of a small compound allosteric inhibitor.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: January 12, 2016
    Assignees: SANOFI, VIB VZW, LIFE SCIENCES RESEARCH PARTNERS VZW, VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Peter Carmeliet, Frederik De Smet, Joost Schymkowitz, Frédéric Rousseau, Corentin Herbert